Injectable study drug for advanced solid tumors
Part of Cancer clinical trials.
This study tests an investigational drug called ALK-N001 for people with advanced solid tumors that have not responded to standard treatment or cannot tolerate it. It aims to see if the drug can help shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have an advanced or metastatic solid tumor (a cancer that has spread and cannot be removed by surgery).
- You have already tried at least one standard treatment, or you cannot tolerate standard treatment.
- You have at least one measurable tumor (a tumor that can be seen on a scan and is not in a previously irradiated area).
- You are in good enough health to be up and about (able to do light activities) and are expected to live at least 3 more months.
- You have not used certain treatments (such as chemotherapy, radiation, immunotherapy) within the past 4 weeks, and you have not taken irinotecan or similar drugs before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, ALK201, in people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and can shrink tumors.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This trial tests an investigational drug called ALK-N001 given as an injection for people with advanced gastrointestinal cancers. It aims to see if the drug can slow or stop tumor growth, and if it's safe to take.
This trial tests a new drug called ALK202 for people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and to find the best dose.
This early-stage study tests neladalkib (NVL-655), a medicine designed to attack ALK-positive cancer. It may help people with advanced ALK-mutated or ALK-rearranged solid tumors, especially ALK-positive non-small cell lung cancer.
This trial tests a new pill, SY-12321, for people with advanced cancer that has a specific change called ALK. The study aims to see if the drug can shrink tumors or slow their growth, and it may be an option if you've already tried other ALK-targeting treatments.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.